TB-500 for Intestinal Healing & Gut Barrier Repair — Gut
Thymosin Beta-4 peptide for gut mucosal repair, intestinal inflammation, leaky gut, and accelerated GI healing.
Overview
TB-500 (Thymosin Beta-4) is a regenerative peptide that promotes tissue repair, angiogenesis, and reduces inflammation throughout the body, including the gastrointestinal tract. It enhances cell migration via actin-sequestering activity, promotes stem cell activation, and accelerates healing of intestinal mucosa. Clinical evidence shows elevated Tβ4 levels in IBD patients (suggesting compensatory healing response) and preclinical studies demonstrate suppression of experimental colitis, reduced oxidative stress, and enhanced wound healing (42-61% faster reepithelialization). Tβ4 inhibits TNF-α-induced NF-κB activation (key IBD pathway), strengthens intestinal tight junctions, and reduces gut permeability. Particularly effective for gut barrier dysfunction, inflammatory bowel conditions, and post-surgical GI healing when used alone or in combination with BPC-157.
Indications
- Leaky gut syndrome and intestinal permeability
- Inflammatory bowel disease support (IBD)
- Gut mucosal damage and ulceration
- Post-surgical intestinal healing
- Chronic gut inflammation
- NSAID-induced gut injury
- Gut-brain axis dysfunction
Mechanism of Action
Intestinal inflammation, tight junction damage, and increased permeability create leaky gut syndrome
Dosing
| Compound | Dose | Frequency | Notes |
|---|---|---|---|
| TB-500 | 2-5 mg | Once or twice daily on empty stomach | Lower bioavailability but direct mucosal contact, good for gut barrier repair |
| TB-500 | 2-5 mg | Twice weekly | Systemic regenerative effects with improved gut healing |
| TB-500 | 5-7.5 mg | 3 times weekly | For severe gut damage or acute IBD flares |
| TB-500 5mg + BPC-157 500mcg | As specified | Twice weekly SC | Synergistic gut healing, enhanced angiogenesis and barrier repair |
Evidence Grade
GRADE C
Safety & Contraindications
- Emerging therapeutic with limited long-term human data
- Generally well-tolerated in preclinical and anecdotal reports
- May cause mild injection site reactions with SC administration
- Oral bioavailability is lower but provides direct gut contact
- Use sterile technique for all injections
- Monitor for any unusual GI symptoms during use